If your child takes stimulant medication for ADHD, or a doctor has suggested starting it, you have probably wondered whether the first prescription was the right pick. A yearlong randomized trial from the University of Sydney, one of the few head-to-head comparisons of the two leading stimulants over an extended period, found that dexamphetamine and methylphenidate improved children’s symptoms equally well. The difference showed up somewhere else: on the scale. Children taking dexamphetamine lost an average of 1.4 kilograms in the first three months, while children on methylphenidate lost about 300 grams and ended the year slightly heavier than they started. That moves the medication conversation away from “which drug is stronger” and toward a question parents are far better positioned to answer: which tradeoffs fit this particular child.
A yearlong randomized trial compared the two most commonly prescribed ADHD stimulants head to head and found no difference in symptom control. Here is what the trial showed, and the questions it hands parents.
Common questions
Which ADHD medication works better for children, dexamphetamine or methylphenidate?
Do ADHD stimulant medications affect a child’s growth?
Should my child switch ADHD medication because of weight loss?
Is medication the only way to help a child with ADHD?
A yearlong head-to-head trial found the two leading ADHD stimulants control children's symptoms equally well. The real difference is weight. That changes the question parents should be asking.
What happened
Researchers at the University of Sydney and the Nepean Blue Mountains Local Health District ran an open-label randomized controlled trial with 100 children aged 4 to 16 who had been diagnosed with ADHD and had never taken stimulant medication. Each child was randomly assigned to dexamphetamine or methylphenidate and followed for 12 months, with the trial conducted between 2016 and 2020. The results were published July 17 in the Journal of Paediatrics and Child Health.
Both groups showed substantial improvement in attention, hyperactivity, and oppositional behavior, with no significant difference in effectiveness between the medications. Most children stayed on the treatment they started with; 62 of the original 100 were still on their assigned medication at the one-year mark. Height growth showed no significant difference between the two groups.
“Both medications worked equally well for improving ADHD symptoms, and most children remained on their original treatment over the first year,” said lead researcher Dr Alison Poulton, Senior Lecturer in Paediatrics and Child Health at the University of Sydney’s Nepean Clinical School. “The main difference was that children taking dexamphetamine experienced greater weight loss, which is an important consideration when choosing treatment and monitoring growth.”
Both medications worked equally well for improving ADHD symptoms, and most children remained on their original treatment over the first year. The main difference was that children taking dexamphetamine experienced greater weight loss, which is an important consideration when choosing treatment and monitoring growth,” said Dr Alison Poulton, Senior Lecturer in Paediatrics and Child Health, University of Sydney, the study’s lead researcher.
Laura Lurns · Learning Success expert
The question the headlines get backwards
Much of the coverage frames this as a warning about one drug. A U.S. News headline reads “One type of ADHD med may affect kids’ weight.” That framing turns a tie into a scare story. The actual finding cuts the other way: with symptom control equal, potency stops being the deciding factor. What decides is fit: appetite, growth, sleep, and how a specific child responds. Those are exactly the things a parent observes across hundreds of dinners and bedtimes, while a prescriber sees a snapshot in a fifteen-minute visit.
The second correction matters even more. A pill that improves attention symptoms is a support for learning, not the learning itself. Attention, working memory, and self-regulation are skills that strengthen with the right kind of practice, and a well-chosen medication opens a window for that practice rather than replacing it. A diagnosis describes where your child is today. It does not predict where they’ll be in a year of the right kind of practice. Families who treat medication as one tool inside a broader plan to build focus and attention skills get more out of both.
This trial also retires a piece of waiting-room folklore: the idea that one stimulant is the strong one and the other the gentle one. Twelve months of randomized, head-to-head data found no difference in symptom control. The differences that remain are the ones families live with day to day, which is precisely why parents belong at the center of this decision.
Key takeaways
- A genuine head-to-head: 100 children, randomized and followed 12 months; dexamphetamine and methylphenidate improved ADHD symptoms equally.
- Weight is the real difference: dexamphetamine averaged 1.4 kg of loss in three months; methylphenidate about 300 grams.
- The better question: with effectiveness tied, fit and growth monitoring should drive the choice, not assumed potency.
What this means for your child
If your child is starting or already taking a stimulant, this study hands you a short list of questions worth asking at the next appointment. What is the plan for tracking weight and height, especially during the first three months, when the dexamphetamine group lost the most? If eating drops off, what happens next: adjusted dose timing, breakfast before the morning dose settles in, calorie-dense snacks after school, or a medication change? The study authors write that either drug is a reasonable initial choice in specialist practice, with methylphenidate “preferred when weight loss is a particular concern.”
There is also reassurance here for families considering a switch. Because symptom control was equal on average, a child who struggles with appetite or weight on one stimulant is not condemned to choose between eating well and focusing well. A different medication, schedule, or dose stays on the table without giving up effectiveness, and that decision belongs with your prescriber and your own careful notes.
The forward-looking piece is the one no prescription covers: whichever medication your child takes, the skills still have to be built. Keep the movement, the sleep routine, and the daily focus practice running alongside the pill bottle, because that combination, not the brand name on the label, is what a year of progress is made of.
Parents get told the medication decision is technical and best left to the experts, and this trial says the opposite: once symptom control is equal, the deciding evidence is the kind only you collect, appetite at dinner, energy at practice, growth over months. The villain here is not either medication, it is the one-size horse-race framing that treats children as interchangeable and parents as spectators. Whichever prescription you and your doctor land on, the focus and self-regulation skills still have to be built, and Brain Bloom develops exactly those underlying skills so the window medication opens gets used: https://learningsuccess.ai/brain-bloom/?utm_source=blog&utm_medium=organic&utm_campaign=adhd-medication-choice-never-about-which-works-better&utm_content=kicker
See what All Access gives your child
Explore Focus Foundations
Is your child struggling in school?
Get your free personalized learning roadmap
You describe what you see at home. We turn it into a plan you start this week.
- Answer 5 short questionnaires about what you already notice, 30–45 minutes at your own kitchen table
- Your child sits no test and gets no score: nothing to schedule, nothing for them to dread
- You do the answering, the AI does the writing, and a person reviews it before it reaches you
- Access all 40+ courses instantly: reading, math, focus, processing and more, with new ones added regularly
Why we use AI, plainly: it writes from a knowledge base our team maintains and audits. We work through it line by line and pull anything the evidence stops supporting. The roadmap you get on Tuesday reflects what we corrected on Monday, and a human still reads it before you do.
Your school district must evaluate your child free of charge if you ask in writing, whatever your income and whatever the outcome (US, 34 CFR 300.111 and 300.301(b)). That route takes time and answers a different question than you do. This one starts today, from what you already know.
Your answers stay yours. We do not sell your personal information, and we do not hand identifiable assessment data to outside AI companies to train their models.
A screener is a starting point, not a diagnosis. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a vision, hearing or medical cause, pursue a professional evaluation too. That is the only route to those supports.
References
- University of Sydney — Leading ADHD medications found to be equally effective in children, with one key difference
- News-Medical — Dexamphetamine and methylphenidate work similarly for ADHD but differ in weight effects
- HealthDay — More Weight Loss Reported With Dexamphetamine Versus Methylphenidate for ADHD
- Mirage News — Top ADHD Drugs Equally Effective for Kids, Key Difference
